A phase I/II clinical trial of Ad-SGE-REIC for malignant pleural mesothelioma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs Ad SGE DKK3 gene therapy-Kyorin (Primary)
- Indications Mesothelioma; Pleural disorders
- Focus Adverse reactions
- Sponsors Kyorin Pharmaceutical
- 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Jun 2016 New trial record
- 05 Nov 2015 Status changed from not yet recruiting to recruiting.